| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 980 | 2012 |
| NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ... Nature medicine 21 (8), 914-921, 2015 | 909 | 2015 |
| Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors A Badros, D Weikel, A Salama, O Goloubeva, A Schneider, A Rapoport, ... Journal of clinical oncology 24 (6), 945-952, 2006 | 773 | 2006 |
| Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients B Barlogie, R Desikan, P Eddlemon, T Spencer, J Zeldis, N Munshi, ... Blood, The Journal of the American Society of Hematology 98 (2), 492-494, 2001 | 739 | 2001 |
| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 624 | 2020 |
| Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy M Zangari, E Anaissie, B Barlogie, A Badros, R Desikan, AV Gopal, ... Blood, The Journal of the American Society of Hematology 98 (5), 1614-1615, 2001 | 597 | 2001 |
| Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ... Leukemia 27 (4), 780-791, 2013 | 405 | 2013 |
| Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities R Desikan, B Barlogie, J Sawyer, D Ayers, G Tricot, A Badros, M Zangari, ... Blood, The Journal of the American Society of Hematology 95 (12), 4008-4010, 2000 | 400 | 2000 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 398 | 2016 |
| Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, ... Journal of Clinical Oncology 33 (6), 657-664, 2015 | 390 | 2015 |
| Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, ... Haematologica 98 (11), 1753, 2013 | 362 | 2013 |
| Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer AP Rapoport, EA Stadtmauer, N Aqui, A Badros, J Cotte, L Chrisley, ... Nature medicine 11 (11), 1230-1237, 2005 | 361 | 2005 |
| Results of autologous stem cell transplant in multiple myeloma patients with renal failure A Badros, B Barlogie, E Siegel, J Roberts, C Langmaid, M Zangari, ... British journal of haematology 114 (4), 822-829, 2001 | 335 | 2001 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 296 | 2017 |
| Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma A Badros, AM Burger, S Philip, R Niesvizky, SS Kolla, O Goloubeva, ... Clinical Cancer Research 15 (16), 5250-5257, 2009 | 282 | 2009 |
| Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years A Badros, B Barlogie, E Siegel, C Morris, R Desikan, M Zangari, A Fassas, ... British journal of haematology 114 (3), 600-607, 2001 | 277 | 2001 |
| Neurotoxicity of bortezomib therapy in multiple myeloma: a single‐center experience and review of the literature A Badros, O Goloubeva, JS Dalal, I Can, J Thompson, AP Rapoport, ... Cancer 110 (5), 1042-1049, 2007 | 259 | 2007 |
| Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning A Badros, B Barlogie, E Siegel, M Cottler-Fox, M Zangari, A Fassas, ... Journal of clinical oncology 20 (5), 1295-1303, 2002 | 241 | 2002 |
| Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma WG Tong, R Chen, W Plunkett, D Siegel, R Sinha, RD Harvey, AZ Badros, ... Journal of clinical oncology 28 (18), 3015, 2010 | 239 | 2010 |
| High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH J Shaughnessy Jr, E Tian, J Sawyer, K Bumm, R Landes, A Badros, ... Blood, The Journal of the American Society of Hematology 96 (4), 1505-1511, 2000 | 239 | 2000 |
